Clinical Trials Logo

Pertussis/Whooping Cough clinical trials

View clinical trials related to Pertussis/Whooping Cough.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05847322 Recruiting - Clinical trials for Pertussis/Whooping Cough

Periscope Phase C Bordetella Pertussis Human Challenge Study With Delayed Antibiotic Therapy for 6 Weeks

Start date: December 6, 2022
Phase: N/A
Study type: Interventional

Primary objective- To assess the safety of nasal inoculation of healthy volunteers with B. pertussis with antibiotic therapy given to eradicate colonisation at 6 weeks after inoculation or at symptom onset, whichever occurs first Secondary objectives - To measure the rate of natural clearance of carriage of B. pertussis following nasal inoculation - To assess the kinetics of B. pertussis colonisation density following nasal inoculation - To describe the microevolution of B. pertussis and adaptation of the resident microbiome during B. pertussis carriage - To measure B. pertussis-specific antibody and cellular immunological responses in healthy volunteers during colonisation with B. pertussis - To identify biomarkers that correlate with natural clearance of B. pertussis carriage after induced B. pertussis colonisation - To detect transmission of B. pertussis to bedroom contacts of inoculated volunteers during prolonged asymptomatic colonisation

NCT ID: NCT04807712 Recruiting - Children, Only Clinical Trials

Pediatric Pertussis in Ambulatory Settings

ACTIVCOQ
Start date: May 30, 2001
Phase:
Study type: Observational

Since 2002, Whooping cough surveillance in pediatric private practice has been set up in France. The results of the first years, 2002-2006, have confirmed the effectiveness of the Pertussis whole-cell (Pw) vaccine and in particular the duration of protection of 9/10 years. After evaluating cases in children vaccinated with Pw vaccines, the study aims today to analyze cases in children vaccinated with Pertussis acellular (Pa) vaccines used since 2002/2003 and to assess, on an outpatient basis, the impact of new vaccine recommendations in France (in 2013, introduction of a 2 + 1 schedule - 8 weeks, 4 months and a 11-month recall - and a 6-year recall, and in 2014, update in the recommendations of exams to be prescribed based on the child's age and vaccination status).